Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Outlook for the Influenza Vaccines Market Heading Into 2029?

The market size for influenza vaccines has seen substantial growth in the previous years. The market is expected to escalate from $8.5 billion in 2024 to a whopping $9.04 billion in 2025, with a compound annual growth rate (CAGR) of 6.3%. The noticeable growth during the historic period can be credited to the need for pandemic preparedness, initiatives taken for public health, studies on the effectiveness of the vaccine, recommendations from healthcare professionals, and monitoring of global influenza.

The market for influenza vaccines is projected to experience substantial expansion in the coming years. It’s predicted to reach $12.13 billion by 2029, with a compound annual growth rate (CAGR) of 7.6%. This surge within the forecast timeframe is due to a combination of factors such as environmental and climate variables, enhanced healthcare access, the introduction of new influenza variants, innovations in adjuvants and delivery systems, and increased healthcare spending. Key trends predicted in the forecast period include an increased adoption of mRNA vaccine technology, a focus on pediatric immunization, measures to control seasonal influenza, improved vaccination outreach in developing countries, and customized vaccination strategies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11935&type=smp

Which Factors Are Pushing The Influenza Vaccines Market Forward?

The increasing prevalence of seasonally occurring flu is anticipated to drive the influenza vaccine market’s expansion. Seasonal influenza is a respiratory illness triggered by influenza viruses, normally circulating and leading to infections at certain periods, particularly during colder months. Antigenic drift, population vulnerability, environmental factors, insufficient vaccine coverage, and the absence of universal vaccination have all contributed to this change. Influenza vaccines aid in diminishing seasonal flu incidences by providing immunity against the virus strains in circulation. For instance, the US government department, the Centers for Disease Control and Prevention (CDC), indicated in November 2023 that during the flu season of 2022-2023, there were roughly 31 million flu-related illnesses, 14 million medical visits due to flu, 360,000 hospitalizations related to flu, and 21,000 deaths caused by flu. Hence, the escalating prevalence of influenza seasons is fueling the growth of the market for influenza vaccines.

Which Segment Held The Largest Share In The Influenza Vaccines Market In 2025?

The influenza vaccines market covered in this report is segmented –

1) By Vaccine Type: Inactivated, Live Attenuated

2) By Valency: Quadrivalent, Trivalent

3) By Route Of Administration: Injection, Nasal Spray

4) By Age Group: Pediatric, Adult

5) By Distribution Channel: Hospitals And Pharmacies, Government And Institutional Supply, Other Distribution Channels

Subsegments:

1) By Inactivated: Trivalent Inactivated Vaccines (TIV), Quadrivalent Inactivated Vaccines (QIV)

2) By Live Attenuated: Live Attenuated Influenza Vaccines (LAIV), Quadrivalent Live Attenuated Influenza Vaccines (QLAIV)

How Are Key Trends Driving Expansion In The Influenza Vaccines Industry?

The usage of high-tech vaccine production has become a significant trend in the influenza vaccine market. To maintain their market foothold, firms in this sector are switching to cutting-edge vaccine production techniques. For example, GlaxoSmithKline PLC., a pharmaceutical and biotech company based in the UK, in January 2023, unveiled MAPS, or Multiple Antigen Presenting System, for the creation of vaccines. This innovative method offers a new approach to producing effective vaccines against bacteria and viruses. Moreover, this technology can be utilized to rapidly develop vaccines in the event of an epidemic or pandemic outbreak.

Which Organizations Are Driving Progress In The Influenza Vaccines Industry?

Major companies operating in the influenza vaccines market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi-Aventis LLC., AstraZeneca PLC, GlaxoSmithKline plc., Serum Institute of India Private Limited, Takeda Pharmaceutical Company Limited, Moderna Inc., Viatris Inc., CSL Limited, Seqirus Inc., Daiichi Sankyo Company Limited, China National Pharmaceutical Group Corporation, Shanghai Fosun Pharmaceutical Group Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Shionogi & Co. Ltd., Liaoning Cheng Da Biotechnology Co. Ltd., Novavax AB, Sinovac Biotech Co. Ltd., Green Cross Corporation, Emergent BioSolutions Inc., Walvax Biotechnology Co. Ltd., Hualan Biological Engineering Inc., Valneva SE, Bharat Biotech International Limited, Vaxess Technologies Inc., Osivax, Gamma Vaccines Pty. Ltd.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/influenza-vaccines-global-market-report

Which Region Is Expected To Experience The Highest Growth In The Influenza Vaccines Industry?

North America was the largest region in the influenza vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the influenza vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=11935&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model